Neonatal Expansion Minima Stent System is FDA-approved for neonates, infants, and young children, with potential for ongoing expansion as patients grow. This presents an opportunity to engage pediatric cardiology centers and hospitals focused on congenital heart disease to adopt a growth-friendly stent portfolio.

Global Access Plan Current US availability with explicit plans to expand to Europe and Asia. Sales outreach can target international distributors, regulatory teams, and hospital networks preparing for cross-border adoption and post-market support partnerships.

Clinical Partnership Product development emphasizes collaboration with physicians, families, and hospitals. Leverage these relationships to position Renata Medical as a clinician-driven innovator, seeking advisory roles, case studies, and joint education programs that drive adoption.

Compact Portfolio Fit Small-company scale (11-50 employees) focused on a niche but high-impact indication. Target mid-to-large pediatric cardiology centers and comprehensive congenital program buyers who value innovative devices with long-term growth compatibility.

Digital Evidence Tech stack highlights modern web presence and digital engagement. Use data-driven marketing and virtual demonstrations to reach procurement teams and surgeons, offering clinical data, outcomes dashboards, and easy e-commerce or ordering workflows for devices.